Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis

BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in early clinical trials. To predict side effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohler, Sheila, Afreen, Sehar, Fernandez-Orth, Juncal, Demmerath, Eva-Maria, Molnar, Christian, Wu, Ying, Weiss, Julia Miriam, Mittapalli, Venugopal Rao, Konstantinidis, Lukas, Schmal, Hagen, Kunze, Mirjam, Erlacher, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634190/
https://www.ncbi.nlm.nih.gov/pubmed/33241675
http://dx.doi.org/10.3324/haematol.2020.252130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634190/
https://www.ncbi.nlm.nih.gov/pubmed/33241675
http://dx.doi.org/10.3324/haematol.2020.252130

Ejemplares similares